The role of depression in the prediction of a “late” remission in first-episode psychosis

The role of depression in the prediction of a “late” remission in first-episode psychosis: An analysis of the OPTiMiSE study

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

David Fraguas
Covadonga M. Díaz-Caneja
Laura Pina-Camacho
Inge Winter van Rossum
Baandrup, Lone
Iris E. Sommer
Glenthøj, Birte Yding
René S. Kahn
Stefan Leucht
Celso Arango

Objective: The identification of predictors of psychosis remission could guide early clinical decision-making for treatment of first-episode schizophrenia (FES). Methods: We analyzed two non-independent subsamples of patients with FES ages 18–40 years from the OPTiMiSE study dataset to investigate the demographic and clinical factors that might help to differentiate “late” remitters (i.e., not in remission at week 2 or 4, but achieving remission within a 10-week follow-up period) from non-remitters within the same period. Results: Subsample 1 included 216 individuals (55 females, mean age 25.9 years) treated with amisulpride in an open-label design who were not in remission at week 2. Early symptomatic response between baseline and week 2 (odds ratio (OR) = 4.186, 95% confidence interval (CI) = 2.082–8.416, p < 0.001) and older age (OR = 1.081, 95% CI = 1.026–1.138, p = 0.003) were the only variables significantly associated with a higher probability of psychosis remission at week 4. Subsample 2 was composed of the 72 participants (19 females, mean age 25.1 years) who were not in remission at week 4 and completed a 6-week double-blind randomized trial comparing continuation of amisulpride with switch to olanzapine. Depression at baseline (as measured with the Calgary Depression Scale for Schizophrenia) was significantly associated with a nearly 3-fold lower likelihood of psychosis remission during the 10-week follow-up (hazard ratio = 2.865, 95% CI = 1.187–6.916, p = 0.019). Conclusion: Our results reinforce the importance of assessing depressive symptoms in people with FES and support the relevance of an early response (as early as 2 weeks) as a predictor of clinical outcome in this population. Clinical trials registration: ClinicalTrials.gov identifier: NCT01248195, https://clinicaltrials.gov/ct2/show/NCT01248195.

Originalsprog	Engelsk
Tidsskrift	Schizophrenia Research
Vol/bind	231
Sider (fra-til)	100-107
Antal sider	8
ISSN	0920-9964
DOI	https://doi.org/10.1016/j.schres.2021.03.010
Status	Udgivet - 2021

Bibliografisk note

Funding Information:
Laura Pina-Camacho has received honoraria or grants from Rubio, Takeda, and Rovi, Instituto de Salud Carlos III (Spanish Ministry of Science, Innovation and Universities), and from Fundacion Alicia Koplowitz .

Funding Information:
The OPTiMiSE trial was funded by the European Commission within the 7th Program (HEALTHF2-2010-242114).

Funding Information:
David Fraguas, Covadonga M. D?az-Caneja, Laura Pina-Camacho, and Celso Arango also report funding from the Spanish Ministry of Science, Innovation and Universities, Instituto de Salud Carlos III (SAM16PE07CP1, PI17/00481, PI17/01997, PI17/00997), co-financed by ERDF Funds from the European Commission, ?A way of making Europe?; CIBERSAM; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2); European Union Structural Funds, European Union Seventh Framework Programme under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY), and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS); Fundaci?n Familia Alonso; Fundaci?n Alicia Koplowitz; and Fundaci?n Mutua Madrile?a.Dr. Fraguas has been a consultant and/or has received fees from Angelini, Eisai, IE4Lab, Janssen, Lundbeck, and Otsuka. He has also received grant support from Instituto de Salud Carlos III (Spanish Ministry of Science, Innovation and Universities) and from Fundaci?n Alicia Koplowitz.Dr. D?az-Caneja has received honoraria from Sanofi-Aventis and Abbvie, and grant support from Instituto de Salud Carlos III (Spanish Ministry of Science, Innovation and Universities).Laura Pina-Camacho has received honoraria or grants from Rubio, Takeda, and Rovi, Instituto de Salud Carlos III (Spanish Ministry of Science, Innovation and Universities), and from Fundacion Alicia Koplowitz.Dr. Glenth?j is the leader of Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), which is partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. Her group has also received a research grant from Lundbeck A/S for another independent investigator-initiated study. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administered by them. She has no other conflicts to disclose.

Funding Information:
Dr. Glenthøj is the leader of Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS), which is partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen, and other foundations. Her group has also received a research grant from Lundbeck A/S for another independent investigator-initiated study. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administered by them. She has no other conflicts to disclose.

Funding Information:
David Fraguas, Covadonga M. Díaz-Caneja, Laura Pina-Camacho, and Celso Arango also report funding from the Spanish Ministry of Science, Innovation and Universities , Instituto de Salud Carlos III ( SAM16PE07CP1 , PI17/00481 , PI17/01997 , PI17/00997 ), co-financed by ERDF Funds from the European Commission , “A way of making Europe”; CIBERSAM ; Madrid Regional Government ( B2017/BMD-3740 AGES-CM-2 ); European Union Structural Funds, European Union Seventh Framework Programme under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY), and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916 , Project PRISM, and grant agreement No 777394 , Project AIMS-2-TRIALS); Fundación Familia Alonso ; Fundación Alicia Koplowitz ; and Fundación Mutua Madrileña .

Funding Information:
Dr. Díaz-Caneja has received honoraria from Sanofi-Aventis and Abbvie, and grant support from Instituto de Salud Carlos III (Spanish Ministry of Science, Innovation and Universities).

Funding Information:
Dr. Fraguas has been a consultant and/or has received fees from Angelini, Eisai, IE4Lab, Janssen, Lundbeck, and Otsuka. He has also received grant support from Instituto de Salud Carlos III (Spanish Ministry of Science, Innovation and Universities) and from Fundación Alicia Koplowitz .

Publisher Copyright:
© 2021

ID: 276331884